https://www.selleckchem.com/pr....oducts/eidd-2801.htm
estigations of other drug-drug interactions for optimising dosing in genetically defined subgroups, particularly during drug development.OBJECTIVES Pharmacogenomic testing (PGX) implementation is rapidly expanding, including pre-emptive testing funded by health systems. PGX continues to develop an evidence base that it saves money and improves clinical outcomes. Identifying the potential impact of pre-emptive testing in specific populations may aid in the development of a business case. METHODS We utilized a software tool that can eva
Aimer
Commentaire
Partagez
